Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost
Status:
RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .